China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm Nanyue BioPharming Co., Ltd, one of the first blood products companies in the country, for RMB4.2 billion (USD578 million) in cash. The acquisition aims to ramp up RAAS’ plasma resources and high-quality production base.
Acquisition Details
The deal is structured to enhance RAAS’ position in the blood products market by integrating Nanyue BioPharming’s established plasma collection network and production capabilities. This strategic move is expected to provide RAAS with additional plasma collection centers and a robust production infrastructure, strengthening its overall competitiveness.
Additional Consideration
An additional RMB50 million (USD6.9 million) consideration will be offered if the plasma collection volume of Nanyue Bio reaches 305 tons by 2025. This performance-based incentive underscores the confidence in Nanyue BioPharming’s operational capabilities and the potential for significant growth in plasma collection volumes post-acquisition.-Fineline Info & Tech
Leave a Reply